Literature DB >> 15107370

A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department.

A Fabbri1, S Ruggeri, G Marchesini, A Vandelli.   

Abstract

OBJECTIVE: To review the results of a comprehensive drug screening as first line diagnostic tool in patients attending an emergency department for suspected drug poisoning.
METHODS: A comprehensive drug screening was carried out in plasma or urine, or both, of 310 patients combining an HPLC multidrug profiling system and a fluorescence polarisation immunoassay.
RESULTS: In 64.2% of cases the screening confirmed the diagnosis of drug poisoning, in 13.9% suspected drugs were measurable at non-toxic concentrations, and in 21.9% no drugs were found. The suspected drugs were fully confirmed in a minority of cases, (symptomatic patients: 28.2% compared with asymptomatic: 16.5%). Symptomatic patients were less likely to have at least one suspected drug (29.6% compared with 57.7%; p<0.001), and more likely to have at least one unsuspected drug found at analysis (17.4% compared with 3.1%; p = 0.005). In 5% of patients, asymptomatic when first observed, one or more unsuspected drugs were found. In 6 of 29 patients, with suspected poisoning of an unspecified drug, the screening identified the specific drug and excluded acute intoxication in the remaining cases.
CONCLUSION: A rapid comprehensive drug screening adds to the diagnosis of patients with suspected drug poisoning, identifying unsuspected drugs in symptomatic patients and excluding drugs in asymptomatic subjects.

Entities:  

Mesh:

Year:  2004        PMID: 15107370      PMCID: PMC1726316          DOI: 10.1136/emj.2003.012344

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  19 in total

Review 1.  A review of biological indicators of illicit drug use, practical considerations and clinical usefulness.

Authors:  K Wolff; M Farrell; J Marsden; M G Monteiro; R Ali; S Welch; J Strang
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

2.  Implications of discordance between clinical impression and toxicology analysis in drug overdose.

Authors:  A S Brett
Journal:  Arch Intern Med       Date:  1988-02

3.  Findings of ten years of clinical drug screening.

Authors:  D J McCoy; J H Trestrail
Journal:  Vet Hum Toxicol       Date:  1988-02

4.  Crisis in drug testing. Results of CDC blind study.

Authors:  H J Hansen; S P Caudill; D J Boone
Journal:  JAMA       Date:  1985-04-26       Impact factor: 56.272

5.  Impact of drug screening in suspected overdose.

Authors:  A L Kellermann; S D Fihn; J P LoGerfo; M K Copass
Journal:  Ann Emerg Med       Date:  1987-11       Impact factor: 5.721

6.  Drug screening versus history in detection of substance use in ED psychiatric patients.

Authors:  J Perrone; F De Roos; S Jayaraman; J E Hollander
Journal:  Am J Emerg Med       Date:  2001-01       Impact factor: 2.469

7.  The utility of toxicologic analysis in children with suspected ingestions.

Authors:  M G Belson; H K Simon; K Sullivan; R J Geller
Journal:  Pediatr Emerg Care       Date:  1999-12       Impact factor: 1.454

8.  Comprehensive toxicology screening in the emergency department: an aid to clinical diagnosis.

Authors:  R L Taylor; S L Cohan; J D White
Journal:  Am J Emerg Med       Date:  1985-11       Impact factor: 2.469

9.  Predicting the clinical course in intentional drug overdose. Implications for use of the intensive care unit.

Authors:  A S Brett; N Rothschild; R Gray; M Perry
Journal:  Arch Intern Med       Date:  1987-01

10.  Reliability of the toxic screen in drug overdose.

Authors:  J A Ingelfinger; G Isakson; D Shine; C E Costello; P Goldman
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

View more
  1 in total

1.  The accuracy of self-reported drug ingestion histories in emergency department patients.

Authors:  Andrew A Monte; Kennon J Heard; Jason A Hoppe; Vasilis Vasiliou; Frank J Gonzalez
Journal:  J Clin Pharmacol       Date:  2014-07-28       Impact factor: 3.126

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.